Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N04BX02

Comtess(entacapone)

Parkinson Disease

Marketing Authorisation Holder: Orion Corporation

EMA Authorisation: 16/09/1998

INN: entacapone

Indication

Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Comtess — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.